Holen Sie sich die Stockscreener-App
28.24
0.49%
-0.14
Handel nachbörslich:
28.24
Schlusskurs vom Vortag:
$28.38
Offen:
$28.26
24-Stunden-Volumen:
1.06M
Relative Volume:
0.66
Marktkapitalisierung:
$4.87B
Einnahmen:
$1.10B
Nettoeinkommen (Verlust:
$375.65M
KGV:
12.86
EPS:
2.1963
Netto-Cashflow:
$113.59M
1W Leistung:
-3.32%
1M Leistung:
+10.79%
6M Leistung:
+28.19%
1J Leistung:
+15.12%
1-Tages-Spanne:
$27.90
$28.43
1-Wochen-Bereich:
$27.90
$29.85
52-Wochen-Spanne:
$19.69
$29.85
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
28.24 | 5.07B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-23 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - marketbeat.com
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - marketbeat.com
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - marketbeat.com
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView
STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com Canada
Canaccord reiterates Acadia Pharmaceuticals stock rating on products - Investing.com India
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline - Investing.com India
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data - TradingView
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline By Investing.com - Investing.com Nigeria
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance - TradingView
Acadia Pharmaceuticals stock hits 52-week high at $29.81 - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains Fresh Market Attention - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC - marketbeat.com
ACAD Maintains Buy Rating by Needham -- Price Target Raised to $41 - GuruFocus
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 - moomoo.com
ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued - Sahm
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript - AOL.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High: What Now? - Kalkine Media
Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating - moomoo.com
Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD - marketbeat.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week HighWhat's Next? - marketbeat.com
Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says - moomoo.com
Immunic appoints Elena Ridloff to board of directors - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Raised to $39.00 - GuruFocus
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BIVA:ACAD - TradingView
Sei Investments Co. Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - marketbeat.com
Empowered Funds LLC Purchases Shares of 48,982 ACADIA Pharmaceuticals Inc. $ACAD - marketbeat.com
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Acadia CFO Mark Schneyer sells $587k in company stock - Investing.com
Acadia CFO Mark Schneyer sells $587k in company stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at Wall Street Zen - marketbeat.com
Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Mark Schneyer Sells 14,292 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
State Street Corporation (ACAD) discloses 5.3% Acadia Pharma stake on 13G - Stock Titan
What is HC Wainwright's Estimate for ACAD FY2026 Earnings? - MarketBeat
Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
HC Wainwright Analysts Increase Earnings Estimates for ACAD - MarketBeat
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus - Sahm
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations - TradingView
ACADIA PHARMACEUTICALS INC SEC Filing (Aug 5, 2026) - Stock Titan
ACADIA Pharmaceuticals (ACAD) Maintains Rating at Perform -- Pri - GuruFocus
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):